Future prospectives for the management of chronic hepatitis B

Table 3 Response to interferon-α or PEG-interferon-α after having failed a prior course of interferon or response to interferon-α or PEG-interferon-α after having failed a prior course of lamivudine

Author; Journal; Year	Treatment regimen	Pretreatment HBeAg status (n)	HBeAg loss	HBeAg seroconversion (%)	HBV DNA loss (%)	ALT normalisation (%)
Janssen; J Hepatology; 1993[157]	IFN 1.5 MU daily for 4 wk followed by 3 MU daily for 8 wk and then 5 MU daily for 4 wk	Positive (18)		11	17
Carreno; Hepatology; 1999[158]	IFN 9 MU thrice weekly for 24 wk	Positive (27)	41	22	445	22
Munoz; J Hepatology; 2002[159]	IFN 6 MU 5 times weekly for 24 wk	Positive (11)		18	181	18
Munoz; J Hepatology; 2002[159]	IFN 6 MU 5 times weekly for 24 wk	Negative (18)			221	44
Ballauff; Eur J Pediatr;[160]	IFN 5-9 MU/m2 thrice weekly for 16-24 wk	Positive (15)		33	334
Teuber; Z Gastroenterol; 1995[161]		Positive (27)		30	59
Flink; Hepatology; 2004[162]	PEG-IFN-α 2b 100 μg/wk for 32 wk followed by 50 μg/wk for 20 wk	Positive (18)	28		02	22
Lau; J Hepatology; 2005[163]	PEG-IFN-α 2a for 48 wk	Positive (30)		43
Prev lamivudine
Flink; Hepatology; 2004[162]	PEG-IFN-α 2b 100 μg/wk for 32 wk followed by 50 μg/wk for 20 wk	Positive (8)	50		02	47
Lau; J Hepatology; 2005[163]	PEG-IFN-α 2a 180 μg/wk for 48 wk	Positive (31)		32
Marcellin; J Hepatology; 2006[164]	PEG-IFN-α 2a 90-180 μg/wk for median 48 wk	Positive (71)	376	326	4736	51
Marcellin; J Hepatology; 2006[164]	PEG-IFN-α 2a 90-180 μg/wk for median 48 wk	Negative (36)			6736	52

¹LLD 200 copies/mL;

²LLD 400 copies/mL;

³LLD 1.0 × 10⁴ copies/mL;

⁴LLD 4.25 × 10⁵ copies/mL;

⁵LLD 4.81 × 10⁵ copies/mL;

⁶on-treatment responses.